ZTSZoetis Inc.
AI adoption · Q1 2026 earnings call
Health CarePiloting
1
extracted from this call
2 / 5
directional only
Not disclosed
no breakout in this call
AI was mentioned only once on this call, briefly and in passing by CEO Kristin Peck in response to a question about accelerating pipeline timelines. She cited AI as a tool being leveraged across drug discovery, research, development, and regulatory dossier preparation to speed innovation. No quantification, dedicated AI products, partnerships, or financial metrics related to AI were disclosed.
Adopter
See full leaderboard →27/ 100
49
stage: piloting · max spec: 2
0
no quantified disclosure
35
1 scope
internal_use
1 AI mention from this call.
Extracted verbatim from the ZTS Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T2Q&A· CEO· Internal usedo you see any opportunity to significantly pull forward launch time lines for products for new markets like renal and oncology, e.g., by changing trial designs or filing based on surrogate endpoints?
“We're certainly leveraging AI, as I've spoken about before, within our portfolio, both in discovery, research, development and importantly, preparing our dossiers for submission. We think all that can certainly speed it up.”
— Kristin Peck, ZTS earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of AI investment (capex, opex, or R&D spend) was provided.
- No specific AI products, platforms, or named partners were disclosed.
- No metrics on AI-driven productivity gains or time savings in R&D were shared.
- AI was mentioned only in response to an analyst question about pipeline acceleration; no proactive AI disclosure was made in prepared remarks.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.